Amino Acid-Based Boron Carriers in Boron Neutron Capture Therapy (BNCT).

Järvinen, Juulia; Pulkkinen, Herkko; Rautio, Jarkko; Timonen, Juri M.

Interest in the design of boronated amino acids has emerged, partly due to the utilization of boronophenylalanine (BPA), one of the two agents employed in clinical Boron Neutron Capture Therapy (BNCT). The boronated amino acids synthesized thus far for BNCT investigations can be classified into two categories based on the source of boron: boronic acids or carboranes. Amino acid-based boron carriers, employed in the context of BNCT treatment, demonstrate significant potential in the treatment of challenging tumors, such as those located in the brain. This review aims to shed light on the developmental journey and challenges encountered over the years in the field of amino acid-based boron delivery compound development. The primary focus centers on the utilization of the large amino acid transporter 1 (LAT1) as a target for boron carriers in BNCT. The development of efficient carriers remains a critical objective, addressing challenges related to tumor specificity, effective boron delivery, and rapid clearance from normal tissue and blood. LAT1 presents an intriguing and promising target for boron delivery, given its numerous characteristics that make it well suited for drug delivery into tumor tissues, particularly in the case of brain tumors.

BORON-neutron capture therapy; BORON; BORONIC acids; BORON compounds; AMINO acids; BRAIN tumors

Pharmaceutics, 2023, Vol 15, Issue 12, p2663

1999-4923

Academic Journal

10.3390/pharmaceutics15122663